Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label

Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation. In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilla Reddy, Venkatesh, Walker, Michael, Sharma, Pradeep, Ballard, Peter, Vishwanathan, Karthick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980577/
https://www.ncbi.nlm.nih.gov/pubmed/29468841
http://dx.doi.org/10.1002/psp4.12289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980577/
https://www.ncbi.nlm.nih.gov/pubmed/29468841
http://dx.doi.org/10.1002/psp4.12289

Ejemplares similares